The Mesoblast (ASX:MSB) share price jumped 33% in November and could go even higher

The Mesoblast limited (ASX:MSB) share price was on fire in November but has been tipped to go even higher from here…

| More on:
jump in asx share price represented by man jumping in the air in celebration

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast limited (ASX: MSB) share price was one of the best performers on the ASX 200 in November.

The biotechnology company's shares raced a massive 33% higher over the month.

Why did the Mesoblast share price zoom higher in November?

The catalyst for the strong gain by the Mesoblast share price in November was the announcement of a major deal with pharma giant Novartis.

That deal has seen Novartis sign an exclusive worldwide license and collaboration agreement for the development, manufacture, and commercialisation of Mesoblast's mesenchymal stromal cell (MSC) product remestemcel-L for the treatment of COVID-19 Acute Respiratory Distress Syndrome (ARDS).

According to the release, Novartis will pay US$50 million upfront and then upwards of US$1.25 billion in milestone payments.

This news went down very well with analysts at Bell Potter. They described it as a "fantastic deal" for Mesoblast. Furthermore, they like that it provides greater certainty in relation to the manufacturing and commercialisation of the product for COVID-19 ARDS.

Can the Mesoblast share price go higher?

This month, Bell Potter has looked closer at the deal and adjusted its price target accordingly.

The broker has a (speculative) buy rating and $7.40 price target on the company's shares. This is up from $7.00 previously and compares to its last close price of $4.43.

According to the note, Bell Potter has lifted its FY 2021 earnings forecasts to reflect the deal.

It commented: "Over the next 12 months we expect MSB to receive US$32.5m in milestones from partner Grunenthal for back pain product and US$105m from partner NVS for successful results from Phase 3 trial and approval for COVID-19 ARDS for remestemcel-L. In addition, US$35m is available to MSB on its existing debt facilities, which provides a runway to at least year end FY22."

What else did it say?

There are also a number of catalysts on the horizon which it feels could take its shares higher.

"Phase 3 COVID-19 ARDS trial has surpassed recruitment of 180 patients required for third and final interim analysis, which we expect to be completed by mid-Dec'20. The trial is now expected to complete recruitment in early 1QCY21, with results later in 1QCY21. Results from both Phase 3 back pain and heart failure trials are expected in Dec'20, which we expect will be key catalysts for the stock, given these indications account for the majority of our valuation for MSB," it concluded.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ⏸️ ASX Shares

a woman wearing a close-sitting hat featuring wires and thick computer screen glasses clutches her computer monitor and looks shocked and disturbed as she reads old-fashioned computer text from the screen.
Technology Shares

Here's why ASX 200 tech shares (ASX:XTX) outperformed today

ASX tech shares have taken a turn for the better today.

Read more »

Worker in hard hat looks puzzled with one hand on chin
Resources Shares

Why did the Rio Tinto share price (ASX:RIO) have such a lousy 2021?

We look at what happened to this ASX 200 mining giant's shares last year

Read more »

a miner wearing a hard hat smiles as he stands in front of heavy earth moving equipment on a barren mine site.
Share Gainers

Here's why the Rumble Resources (ASX:RTR) share price is climbing 5%

The mineral explorer's share price is on the rise amid promising drill results.

Read more »

share price high, all time record, record share price, highest, price rise, increase, up,
⏸️ ASX Shares

Here are the top 10 ASX 200 shares on Wednesday

Here are your top 10 biggest gainers in the ASX 200 on Wednesday.

Read more »

comical investor reading documents and surrounded by calculators
⏸️ ASX Shares

The ASX reporting wrap-up: WiseTech, Bravura, Seven Group

Just what the investor ordered. Here’s a recap of the companies that reported on Wednesday...

Read more »

Doctor performing an ultrasound on pregnant woman
⏸️ ASX Shares

The ASX reporting wrap-up: Ansell, Kogan, Nanosonics

Just what the investor ordered. Here’s a recap of the companies that reported on Tuesday...

Read more »

blue arrows representing a rising share price ASX 200
⏸️ ASX Shares

Here are the top 10 ASX 200 shares on Tuesday

Here are your top 10 biggest gainers in the ASX 200 on Tuesday.

Read more »

unhappy investor considering computer screen
Share Market News

The ASX reporting wrap-up: Charter Hall, Ampol, NIB Holdings

Just what the investor ordered. Here’s a recap of the companies that reported on Monday...

Read more »